GlobeNewswire Clinical StudiesOriginal article
Revagenix Doses First Participant in Phase 1 Trial of Rev-56, an Inhaled Therapy for Non-CF Bronchiectasis
Phase 1Rev-56Positive
AI Analysis
Summary
Revagenix has dosed the first participant in a Phase 1 clinical trial of Rev-56, a first-in-class inhaled anti-pseudomonal therapy for non-CF bronchiectasis.
Clinical Trial Data
Phase
Phase 1
Importance:5/10
Sentiment:
0.50
Phase 1Clinical TrialInhaled TherapyFirst-in-ClassNCFB
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 27, 2026 1:02 PM